Study to Investigate the Treatment Effect of Colchicine in Patients With COVID-19

• ClinicalTrials.gov Identifier: NCT04667780
• Recruitment Status: Recruiting
• First Posted: December 16, 2020
• Last Update Posted: December 16, 2020
• Sponsor: Ayub Teaching Hospital
• Collaborator: Universidad de Murcia
• Information provided by (Responsible Party): Dr Umer Farooq, Ayub Teaching Hospital

Study Description

Brief Summary:

COVID-19 is associated with a cytokine storm that leads to respiratory distress, multiorgan failure and elevated mortality. Oral Colchicine exhibits high anti-inflammatory capacity attributed to the inhibition of microtubules polymerization, inflammasome and production of IL-1β and IL-6, which could prevent the inflammatory storm in COVID-19 patients at risk. The investigators present a randomized, controlled, open-labeled, and pragmatic clinical trial to study the treatment effect of Colchicine in COVID-19 patients requiring hospitalization, but no intensive care yet. Colchicine will be started within the first 48 hours and continue for 14 days using a descending dose. The benefits will be studied in terms of clinical evolution (WHO 7-point scale) and IL-6 levels, as well as other clinical and biochemical secondary end-points. In the case of positive results, the clinical impact would be relevant given that this oral medication is affordable and widely accessible which would help to prevent the inflammatory complications associated with COVID-19.

Condition or disease	Intervention/treatment	Phase
COVID-19	Drug: Colchicine; Drug: Standard COVID-19 care	Phase 3

Detailed Description:

This is a Phase III, prospective, pragmatic, randomized, controlled and open-label trial, comparing standard of care vs. standard of care plus COLCHICINE for 14 days, in patients hospitalized due to COVID-19 and confirmed infection by SARS-CoV-2, within the first 48 hours after the hospital admission. Patients meeting severity criteria will be excluded, defined as established limitation of therapeutic effort or need for invasive mechanical ventilation at the time of inclusion. The Colchicine treatment includes an initial dose of 1.5 mg (1 mg and 0.5 mg two hours after), followed by 0.5 mg every 12 hours during the next 7 days and 0.5 mg every 24 hours until the completion of 14 days of total treatment. In patients receiving ritonavir or lopinavir or with reduced renal clearance (<50 ml/min/1.37m2), weight <70 kg or age >75 years old, the dose will be adjusted to the half.

Patients meeting all the inclusion criteria and none of the exclusion ones (see below), after signing the informed consent, will be centrally randomized to "Colchicine" or "Control" group. Patients in both groups will receive the standard therapy for COVID-19 as per the hospital protocols. Randomization will be controlled by: age, sex, time from initiation of symptoms, cardiovascular disease, the 7 point WHO and levels of C-reactive protein, ferritin, D-dimer, IL-6 and lymphocyte levels.

Study Design

• Study Type: Interventional (Clinical Trial)
• Estimated Enrollment: 102 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Intervention Model Description: Phase III, prospective, randomized, controlled, open-label and pragmatic trial, comparing the administration of Colchicine plus standard treatment vs. standard therapy, in hospitalized patients with COVID-19, within the first 48 hours, and no severity criteria.
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: Study to Investigate the Treatment Effect of Colchicine in Patients With COVID-19
• Actual Study Start Date: December 10, 2020
• Estimated Primary Completion Date: May 9, 2021
• Estimated Study Completion Date: July 9, 2021

Arms and Interventions

Arm	Intervention/treatment
Experimental: Colchicine; This arm will receive Standard COVID-19 care + Colchicine The Colchicine treatment includes an initial dose of 1.5 mg (1 mg and 0.5 mg two hours after), followed by 0.5 mg every 12 hours during the next 7 days and 0.5 mg every 24 hours until the completion of 14 days of total treatment. In patients receiving ritonavir or lopinavir or with reduced renal clearance (<50 ml/min/1.37m2), weight <70 kg or age >75 years old, the dose will be adjusted to the half.	Drug: Colchicine; Colchicine tablet 0.5 mg; Drug: Standard COVID-19 care; As per the hospital guidelines
Control - Standard COVID-19 care; This arm will receive standard COVID-19 care as per the hospital guidelines.	Drug: Standard COVID-19 care; As per the hospital guidelines

Outcome Measures

Primary Outcome Measures :

1. Changes in the patients' clinical status through the 7 points ordinal scale WHO R&D Blueprint expert group [ Time Frame: up to 14 days ]
   Improvement in the clinical evolution of patients
2. Changes in IL-6 concentrations [ Time Frame: up to 14 days ]
   Improvement in cytokine level

Secondary Outcome Measures :

1. Improvement in the clinical status [ Time Frame: up to 14 days ]
   time needed to reduce at least 2 points in the 7-point Ordinal Scale for Clinical Improvement by WHO R&D Blueprint expert group (0-7)
2. Changes in the score for the Sequential Organ Failure Assessment (SOFA score) [ Time Frame: up to 14 days ]
   Sequential Organ Failure Assessment (SOFA score) (0-14)
3. Changes in the punctuation in the National Early Warning Score [ Time Frame: up to 14 days ]
   National Early Warning Score (NEWS scale)
4. Number of days with invasive mechanical ventilation [ Time Frame: up to 14 days ]
5. Number of days with high flow oxygen therapy [ Time Frame: up to 14 days ]
6. Changes in other inflammatory markers [ Time Frame: up to 14 days ]
   C-reactive protein
7. Changes in severity markers [ Time Frame: up to 14 days ]
   D-dimer
8. Changes in severity markers [ Time Frame: up to 14 days ]
   Leukocytes
9. Changes in severity markers [ Time Frame: up to 14 days ]
   Lymphocytes
10. Changes in severity markers [ Time Frame: up to 14 days ]
    Platelets
11. Changes in severity markers [ Time Frame: up to 14 days ]
    LDH
12. Changes in severity markers [ Time Frame: up to 14 days ]
    Ferritin
13. Changes in myocardial damage [ Time Frame: up to 14 days ]
    myocardial stress markers hsTnT
14. Changes in myocardial damage [ Time Frame: up to 14 days ]
    myocardial stress markers NT-proBNP
15. Time until reaching a virus negative status [ Time Frame: up to 14 days ]
    RT-PCR assay
16. Length of hospital stay [ Time Frame: up to 14 days ]
    Length of hospital stay
17. Number of days in the intensive care unit. [ Time Frame: up to 14 days ]
    Number of days in the intensive care unit.
18. Mortality [ Time Frame: up to 14 days ]
    Mortality

Eligibility Criteria

• Ages Eligible for Study: 18 Years to 65 Years (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

1. SARS-CoV-2 infection confirmed by PCR.
2. Admitted in the hospital in the previous 48 hours, with clinical status 3, 4 or 5 of WHO classification.
3. Age above 18 years old.
4. Informed written consent.

Exclusion Criteria:

1. Invasive mechanical ventilation needed.
2. Established limitation of the therapeutic effort
3. Inflammatory bowel disease (IBD: Chron Syndrome or Ulcerative colitis), chronic diarrhea or malabsorption.
4. Previous neuromuscular disease.
5. Other disease with an estimated vital prognosis under 1 year.
6. Severe renal insufficiency (glomerular filtration rate <30 mL/min/1.73m2)
7. Medical records of cirrhosis, active chronic hepatitis or severe hepatic disease defined by GOT or GPT levels three times above the normal upper limit.
8. Patients with previous colchicine treatment for other diseases (mainly chronic prescriptions for familial Mediterranean fever or gout). Clearance period will not be required for patients treated with colchicine who stopped the treatment before the randomization.
9. Patients with history of allergic reaction or significant sensitivity to colchicine.
10. Treatment with immunosuppressive agents, corticoids or interleukine-1 antagonists for 6 months before inclusion.
11. Pregnant or breastfeeding female, confirmed by a positive result in the human chorionic gonadotropin (hCG) test.
12. Fertile woman, or post-menopausal during less than one year and non-surgically sterilized. Women of fertile age may be included if using at least one contraceptive method and preferably two complementary contraceptive methods.
13. Use of other investigational drugs in the moment of inclusion, or during 30 days previous to inclusion.

Contacts and Locations

Contacts

Contact: Dr. Zeeshan Haroon, MBBS; + 92 3175564317; zeeshanharoon@yahoo.com

Locations

Pakistan

Ayub Teaching Hospital; Recruiting

Abbottabad, Khyber Pakhtunkhwa, Pakistan, 22010

Contact: Dr. Zeeshan Haroon, MBBS + 92 317 5564317 zeeshanharoon@yahoo.com

Sponsors and Collaborators

Ayub Teaching Hospital

Universidad de Murcia

More Information

Publications:

Deftereos SG, Giannopoulos G, Vrachatis DA, Siasos GD, Giotaki SG, Gargalianos P, Metallidis S, Sianos G, Baltagiannis S, Panagopoulos P, Dolianitis K, Randou E, Syrigos K, Kotanidou A, Koulouris NG, Milionis H, Sipsas N, Gogos C, Tsoukalas G, Olympios CD, Tsagalou E, Migdalis I, Gerakari S, Angelidis C, Alexopoulos D, Davlouros P, Hahalis G, Kanonidis I, Katritsis D, Kolettis T, Manolis AS, Michalis L, Naka KK, Pyrgakis VN, Toutouzas KP, Triposkiadis F, Tsioufis K, Vavouranakis E, Martinèz-Dolz L, Reimers B, Stefanini GG, Cleman M, Goudevenos J, Tsiodras S, Tousoulis D, Iliodromitis E, Mehran R, Dangas G, Stefanadis C; GRECCO-19 investigators. Effect of Colchicine vs Standard Care on Cardiac and Inflammatory Biomarkers and Clinical Outcomes in Patients Hospitalized With Coronavirus Disease 2019: The GRECCO-19 Randomized Clinical Trial. JAMA Netw Open. 2020 Jun 1;3(6):e2013136. doi: 10.1001/jamanetworkopen.2020.13136.

Scarsi M, Piantoni S, Colombo E, Airó P, Richini D, Miclini M, Bertasi V, Bianchi M, Bottone D, Civelli P, Cotelli MS, Damiolini E, Galbassini G, Gatta D, Ghirardelli ML, Magri R, Malamani P, Mendeni M, Molinari S, Morotti A, Salada L, Turla M, Vender A, Tincani A, Brucato A, Franceschini F, Furloni R, Andreoli L. Association between treatment with colchicine and improved survival in a single-centre cohort of adult hospitalised patients with COVID-19 pneumonia and acute respiratory distress syndrome. Ann Rheum Dis. 2020 Oct;79(10):1286-1289. doi: 10.1136/annrheumdis-2020-217712. Epub 2020 Jul 30.

• Responsible Party: Dr Umer Farooq, Professor, Ayub Teaching Hospital
• ClinicalTrials.gov Identifier: NCT04667780
• Other Study ID Numbers: ATH/IRB/Colchicine/25.11.2020
• First Posted: December 16, 2020
• Last Update Posted: December 16, 2020
• Last Verified: December 2020

Individual Participant Data (IPD) Sharing Statement:

• Plan to Share IPD: No

• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No
• Product Manufactured in and Exported from the U.S.: No

Additional relevant MeSH terms:

Colchicine; Gout Suppressants; Antirheumatic Agents; Tubulin Modulators; Antimitotic Agents; Mitosis Modulators; Molecular Mechanisms of Pharmacological Action; Antineoplastic Agents